Narcolepsy

Chapter

Abstract

Narcolepsy means “to be seized by sleep” and is a relatively rare neurological sleep disorder that is the bane of those afflicted, yet provides a window on the neuromechanisms and functions of sleep. This chapter reviews and examines narcolepsy characteristics, incidence, symptoms, differentiating tests, and appropriate treatment options. Recent evidence is reviewed for the causes and neuromechanisms of narcolepsy and a theoretical triggering neurophysiological mechanism of cataplexy is also discussed. The impact of narcolepsy on day-to-day living and the extraordinary impact of optimal treatment can have positive life altering benefit for some, if not most narcoleptic patients reported from several cases. Finally, some helpful tips regarding physician responsibilities to patients and the public, contact information for the success program for Xyrem, and patient contact information for the Narcolepsy Network are provided.

Keywords

Glaucoma Propranolol Fluoxetine Amphetamine Hyperthyroidism 

References

  1. 1.
    American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed. Diagnostic & coding manual. Westchester, IL: American Academy of Sleep Medicine; 2005.Google Scholar
  2. 2.
    Iber C, Ancoli-Israel S, Chesson A, Quan SF, American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. 1st ed. Westchester, IL: American Academy of Sleep Medicine; 2007.Google Scholar
  3. 3.
    Scrima L. An etiology of narcolepsy-cataplexy and a proposed cataplexy neuromechanism. Int J Neurosci. 1981;15:69–86.PubMedCrossRefGoogle Scholar
  4. 4.
    Pagel JF. Excessive daytime sleepiness. Am Fam Physician. 2009;79(5):391–6.PubMedGoogle Scholar
  5. 5.
    Guilleminault C. Narcolepsy. In: C Guilleminault, WC Dement, P. Passouant, editors. New York: Spectrum Publications. 1976. p. 125–44.Google Scholar
  6. 6.
    Scrima L. Lag time between onset of excessive sleepiness and cataplexy in narcolepsy patients. Sleep Res. 1991;20:328.Google Scholar
  7. 7.
    Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for clinical use of the MSLT and the maintenance of wakefulness test (MWT). Sleep. 2005;28(1):113–21.Google Scholar
  8. 8.
    American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien, IL: American Academy of Sleep Medicine, 2014.Google Scholar
  9. 9.
    Scrima L, Hoddes E, Johnson F, Cardin R, Thomas E, Hiller FC. Effect of high altitude on a patient with obstructive sleep apnea. Sleep Res. 1987;16:427. Abstract.Google Scholar
  10. 10.
    Hartman P, Scrima L. Muscle activity in the legs (MAL) associated with frequent arousals in narcoleptics and OSA patients. Clin Electroencephalogr. 1986;17:181–6.PubMedGoogle Scholar
  11. 11.
    Scrima L. Dreaming, an epiphenomenon of narcolepsy. In: Pagel J, editor, Dreaming & Nightmares, Sleep Med Clin. W.B. Saunders Div. of Elsevier, 2010;5(2):261–275.Google Scholar
  12. 12.
    John J, Thannicakal TC, McGregor R, Ramanathan L, Ohtsu H, Nishino S, Sakai N, Yamanaka A, Stone C, Cornford M, Seigel JM. Greatly increased numbers of histamine cells in human narcolepsy and cataplexy. Ann Neurol. 2013;74:786–93. doi: 10.1002/ana.23968.PubMedCrossRefGoogle Scholar
  13. 13.
    Kantor S, Mochizuki T, Janisiewicz AM, Clark E, Nishino S, Scemmel TE. Orexin neurons are necessary for circadian control of REM sleep. Sleep. 2009;32(9):1127–34.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypcretin (orexin) cells in narcolepsy without cataplexy. Sleep. 2009;32(8):993–8.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Siegel JM. Brainstem mechanisms generating REM sleep. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice sleep medicine. 3rd ed. Philadelphia, PA: W.B. Saunders Co; 2000. p. 112–54.Google Scholar
  16. 16.
    Scrima L, Garlick I, Victor Y, Miller BR. Narcolepsy patients’ blood pressure in higher and lower weight groups. Sleep. 1998;21(Supl):53.Google Scholar
  17. 17.
    Meier-Ewert K, Matsubayashi K, Benter L. Propranolol: long-term treatment in narcolepsy-cataplex. Sleep. 1985;8:95–104.PubMedGoogle Scholar
  18. 18.
    Scrima L, Skakich-Scrima S, Miller BR. The efficacy of gamma-hydroxybutyrate (GHB) in Narcolepstics: 9 Years. Sleep. 2000;23(Abstract suppl):A293.Google Scholar
  19. 19.
    Black J, et al. (investigators in study group). The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol. 2003;41:131–5.Google Scholar
  20. 20.
    Aran A, Ling L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, Zeitzer J, Mignot E. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32(8):979–83.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Han F. Sleepiness that cannot be overcome: narcolepsy and cataplexy. Respirology. 2012;17:1157–65. Abstract.PubMedCrossRefGoogle Scholar
  22. 22.
    Aurora RN, Zak RS, Maganti RR, Auerbach SH, Casey KAR, Chowdhuri S, Karippot A, Raman K, Kristo DA, Margenthaler TI. Best practice guide for treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Scrima L, Miller BR. Pre-onset medical and sleep history of 100 Narcoleptics. Sleep. 1999;22:S155.Google Scholar
  24. 24.
    Mamelak M. Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. Prog Neurobiol. 2009;89(2):193–219.PubMedCrossRefGoogle Scholar
  25. 25.
    Didato G, Boili L. Treatment of narcolepsy. Expert Rev Neurother. 2009;9(6):897–910.PubMedCrossRefGoogle Scholar
  26. 26.
    Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS. Sociaum oxybate for narcolespsy with catapelxy: systematic review and meta-analysis. J Clin Sleep Med. 2012;8(4):451–8.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Scrima L, Garlick I, Victor Y, Miller B, Sullivan M, Olive J, Christ-Molnar T. Narcolepsy patients’ blood pressure and pulse. Sleep Res. 1996;25:366.Google Scholar
  28. 28.
    Guilleminault C, Faul JL, Stoohs R. Sleep-disordered breathing and hypotension. Am J Respir Crit Care Med. 2001;164(7):1242–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Pickering T, Sleight P. Baroreceptors and hypertension. In: DeJong W, Provoost A, Shapiro A, editors. Progress in brain research, vol 47. 1977. p. 43–60Google Scholar
  30. 30.
    Amatruda T, Black D, McLenna T, McCarley W, Hobson J. Sleep cycle control and cholinergic mechanisms: differential effects of carbachol injections at pontine brain stem sites. Brain Res. 1975;98:501–15.PubMedCrossRefGoogle Scholar
  31. 31.
    Jouvet M. The role of monoamines and acetycholine containing neurons in the regulation of the sleep waking cycle. Ergeb Physiol. 1972;64:166–307.PubMedGoogle Scholar
  32. 32.
    Jones B, Harper S, Halaris A. Effects of locus coeruleus lesions upon cerebral monoamine content, sleep wakefulness states and the response to amphetamine in the cat. Brain Res. 1977;124:473–96.PubMedCrossRefGoogle Scholar
  33. 33.
    Palkovits M, Zaborszky L. Neuroanatomy of central cardiovascular control. Nucleus tractus solitarii: afferent and efferent neuronal connections in relation to the baroreceptor reflex arc. In: W DeJong.Google Scholar
  34. 34.
    Ward D, Gunn C. Locus coeruleus complex: elicitation of the pressor response and a brain stem region necessary for its occurrence. Brain Res. 1976A;107:401–6.Google Scholar
  35. 35.
    Ward D, Gunn C. Locus coeruleus complex: differential modulation of depressor mechanisms. Brain Res. 1976B;107:407–11.Google Scholar
  36. 36.
    Schwartz S, Ponz A, Poryazova R, Werth E, Boesiger P, Khatami R, Bassetti C. Abnormal activity in hypothalamus and amygdala during humour processing in human narcolepsy with cataplexy. Brain. 2007;131:1–9. doi: 10.1093/brain/awrn292.CrossRefGoogle Scholar
  37. 37.
    Scrima L, Hartman P, Anderson J, Dandes H, Ramsay E, Winters R, Schneiderman N. The relationship of blood pressure and pulse transit time to narcolepsy and cataplexy. Sleep Res. 1983;12:283.Google Scholar
  38. 38.
    Wise MS, Arand DL, Auger R, Brooks SN, Watson NF. Treatment of narcolepsy and other hypersomnia of central origin. Sleep. 2007;30(12):1712–27.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Bogan RK, Feldman NT, Lankford A, Khayrallah MA. A double-blind, placebo-controlled, randomized, cross-over study of the efficacy and safety of ADX-NO5 for the treatment of excessive daytime sleepiness in adults subjects with narcolepsy. Sleep. 2013;36:A257. Abstract.Google Scholar
  40. 40.
    Scrima L, Hartman P, Johnson FH, Hiller FC. Efficacy of gamma-hydroxybutyrate (GHB) vs placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry. 1989;26:331–43.PubMedCrossRefGoogle Scholar
  41. 41.
    Thorpy MJ, Goswami M. Treatment of narcolepsy. In: Thorpy MJ, editor. Handbook of sleep disorders. New York, NY: Marcel Dekker; 1990. p. 235–58.Google Scholar
  42. 42.
    Glenmullen J. Prozac backlash. New York, NY: Simon & Schuster; 2000.Google Scholar
  43. 43.
    Muyard JP, Laborit HM. Gamma-hydroxybutyrate. In: Forrest IS, Usdin E, editors. PsychopharmacologySeries, volume 2: psychotherapeutic drugs. Part II. applications. New York, NY: Marcel Dekker; 1977. p. 1339–75.Google Scholar
  44. 44.
    Connelly WM, Errington AC, Crunelli V. c-Hydroxybutyric acid (GHB) is not an agonist of extrasynaptic GABAA receptors. PLoS One. 2013;8(11):e79062. doi: 10.1371/journal.pone.0079062.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Scrima L, Hartman P, Johnson FH, Thomas EE, Hiller FC. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep. 1990;13(6):479–90.PubMedGoogle Scholar
  46. 46.
    Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004;27(7):1327–34.PubMedGoogle Scholar
  47. 47.
    Black J, et al. (investigators in study group). A randomized, double-blind, multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25(1):42–9.Google Scholar
  48. 48.
    Scrima L. Gamma-hydroxybutyrate (GHB) treated narcolepsy patients continue to report cataplexy controlled for up to five (5) years. Sleep Res. 1992;21:262.Google Scholar
  49. 49.
    Scrima L, Shander D. Letter to editor on article: narcolepsy review (Aldrich MS: 8-9-91). New Engl J Med. 1991;324(4):270–1.CrossRefGoogle Scholar
  50. 50.
    Black J, et al. (investigators in study group). A 12 month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26(1):31–5.Google Scholar
  51. 51.
    Black J, et al. (investigators in study group). Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5:119–23.Google Scholar
  52. 52.
    Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci. 1979;6:1–6.PubMedGoogle Scholar
  53. 53.
    Mansukhani MP, Kotagal S. Sodium oxybate in the treatment of childhood narcolepsy-cataplexy: a retrospective study. Sleep Med. 2012;13(6):606–10.PubMedCrossRefGoogle Scholar
  54. 54.
    Siegel J. REM sleep anatomy and physiology. In: Kushida editor, The encyclopedia of sleep. 2013;1:460–72.Google Scholar
  55. 55.
    Blouin AM, Fried I, Wilson CL, Staba RJ, Behnke EJ, Lam HA, Maidment NT, Karlsson KAE, Lapierre JL, Siegel JM. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat Commun. 2013.Google Scholar
  56. 56.
    Oishi Y, Williams RH, Agostinelli L, Arrigoni E, Fuller PM. Role of the medial prefrontal cortex in cataplexy. J Neurosci. 2013;33(23):9743–51. doi: 10.1523/Jneurosci. 0499-13, 2013.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Burgess CP, Scammell TE. Narcolepsy: neural mechanisms of sleep and cataplexy. J Neurosci. 5 Se 2012; 32(36):12305–11. doi: 1.1523/Jneurosci. 2630-12, 2012.Google Scholar
  58. 58.
    Boissard R, Gervasoni D, Schmidt MH, Barbafi B, Rort P, Luppi PH. The rat ponto-medullary network responsible for paradoxical sleep onset and maintenance. A combined microinjection and functional anatomical study. Eur J Neurosci. 2002;16:1959–73.PubMedCrossRefGoogle Scholar
  59. 59.
    Jazz Pharmaceuticals presents JZP-110 Phase 2b data for the treatment of EDS symptoms in adults with narcolepsy. Press release June 10, 20114 (late breaking report presented by Black, J et. Al. at Sleep 2014).Google Scholar
  60. 60.
    Golicki D, Bala MM, Niewada M, Wierzbicka A. Modafinil for narcolepsy: systematic review and meta-analysis. Med Sci Monit. 2010;16(8):RA177–86.PubMedGoogle Scholar
  61. 61.
    Mignot E, Hayduk R, Black J, Grumet FC, Gilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1997;20:1012–20.PubMedGoogle Scholar
  62. 62.
    Andlauer O, Moore H, Hong S-C, Dauvilliers Y, Kanbayashi T, Nishino S, Han F, Silber MH, Rico T, Einen M, Kornum BR, Jennum P, Knudsen S, Nevsimalova S, Poli F, Plazzi G, Mignot E. Preedictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep. 2012;35(9):1247–55.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Sleep-Alertness Disorders Center-Consultants, IncAuroraUSA

Personalised recommendations